Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria

Table 1 Summary table on vaccine efficacy

Vaccine assumptions	HPV 16	HPV 18	HPV 31, 33, 45, 52 and 58
Cervical cancer
Vaccine efficacy for preventing cervical HPV16/18/31/33/45/52/58 infections:
- Male^a	0.411	0.621	0.411
- Female^b	0.76	0.963	0.76
Degree of protection of the vaccine against cervical HPV16/18 infections becoming persistent	0.988	0.984	0.988
Degree of protection of the vaccine against HPV16/18 -related CIN	0.979	1	0.979
Vaginal and vulvar cancers
Vaccine efficacy for preventing vaginal/vulvar HPV16/18 infections:
- Male^a	0.411	0.621
- Female^b	0.76	0.963
Degree of protection of the vaccine against vaginal/vulvar HPV16/18 infections becoming persistent	0.988	0.984
Degree of protection of the vaccine against HPV16/18-related /VaIN/VIN	1	1
Anal cancers
Vaccine efficacy for preventing anal infections
- Male^a	0.411	0.621	0.621
- Female^b	0.76	0.963	0.963
Degree of protection of the vaccine against anal infections becoming persistent
- Male^a	0.787	0.96	0.96
- Female^b	0.988	0.984	0.984
Degree of protection of the vaccine against HPV16/18 -related AIN neoplasia	0	0	0
Penile and H&N cancers
Vaccine efficacy for preventing penile and H&N infections
- Male^a	0.411	0.621
- Female^b	0.76	0.963
Degree of protection of the vaccine against penile and H&N infections becoming persistent
- Male^a	0.787	0.96
- Female^b	0.988	0.984
Degree of protection of the vaccine against HPV16/18 -related PIN and H&N neoplasia	0	0

^aPreventing male genital infections through male vaccination is assumed to prevent transmission of genital infections to females
^bPreventing female genital infections through vaccination is assumed to prevent transmission of genital infections to males
Source: Giuliano et al. (2011) [38] and Elbasha and Dasbach (2010) [28]

ISSN: 1471-2334